国家神经系统疾病临床医学研究中心数据管理与共享系统
Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight
第一作者：Ma Yan, Yan
基本信息
- 负责人：Ma Yan, Yan
- 数据来源： CHANCE
- 论文编号：OTHERS20190725
- 发表时间：2018-05-08
2018-05-08
已发表文章
发表杂志：Therapeutics and Clinical Risk Management
发表类型: Original Research
影响因子(IF): 2.423
PMID: 29773949 Pubmed原文链接 全文下载
主要研究背景及目的
方法
All 3,420 male participants coming from the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events trial were divided into 3 groups based on bodyweight (<65 kg, 65-75 kg, and ≥75 kg). The stroke outcomes included stroke recurrence, combined vascular events, and bleeding events during 90 days of follow-up. The interaction of the treatment effects of DAT among patients with different bodyweight was assessed by Cox proportional hazards models.
结论
DAT does not show benefit in patients with higher weight, compared with MAT. Bleeding events found in the DAT group were not more than the MAT group among patients with lower weight.
主要结果
DAT is superior to mono antiplatelet therapy (MAT) for reducing stroke recurrence among patients with weight <65 kg (5.0% vs 11.7%; hazard ratio [HR], 0.41; 95% CI: 0.22-0.76) and 65-75 kg (6.7% vs 10.8%, HR, 0.62; 95% CI: 0.43-0.89). However, no significant difference was found in stroke recurrence between DAT and MAT in patients with weight ≥75 kg (9.4% vs 11.6%; HR, 0.80; 95% CI: 0.58-1.10). A significant interaction was observed between weight and antiplatelet therapy on stroke recurrence (p<0.05). Similar result was found for combined vascular events. More bleeding events were found in DAT group among patients with <65 kg (3.7% vs 2.2%), but with no significant difference.